TNYA

Tenaya Therapeutics, Inc.

Healthcare
Biotechnology
$139M market cap

Forecast run · Sep 14, 2026Upside rank 445 of 3,136

Model Signal

ForecastQ Daily Probabilities

56.9%

61.1%

32.5%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$0.64

Price target$2.33

Implied move+264.1%

Analysts6

ForecastQ Portfolios

TNYA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.